Mycoplasma Testing Market

Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025

Report Code: BT 3371 Nov, 2020, by marketsandmarkets.com

The global mycoplasma testing market size is valued at an estimated USD 689 million in 2020 and is projected to reach USD 1,095 million by 2025, at a CAGR of 9.7% during the forecast period. The global mycoplasma testing market's growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.

Mycoplasma Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Mycoplasma testing market

Recently, several reports have reminded physicians of the possibility of coinfection with other pathogens (such as Mycoplasma pneumoniae) in patients with COVID-19. This signifies the need to test patients with COVID-19 (if they show pneumonia) symptoms for mycoplasma. Such cases are expected to drive the demand for mycoplasma testing in the diagnostic/pathological settings. The rising rate of coinfections in COVID-19 cases, with a significant probability of them being caused by Mycoplasma pneuminiae is expected to drive the demand for mycoplasma tests in several countries across the world in the coming months.

Market Dynamics

Driver: Growing concerns over cell culture contamination

Cell culture contamination is the most common problem encountered in cell culture laboratories. Cell culture contaminants are divided into two main categories, namely, chemical contaminants and biological contaminants. Chemical contaminants include impurities in media, sera, water, endotoxins, plasticizers, and detergents, while biological contaminants include bacteria, mold, yeast, viruses, and mycoplasma as cross-contamination by other cell lines. For contamination detection, various tests, including mycoplasma testing, are used.

Opportunity: Globalization of clinical trials and R&D and harmonization of regulations resulting in increased outsourcing

The primary reasons pharmaceutical and biopharmaceutical companies are opting for outsourcing clinical trials, and R&D are cost efficiency, easy patient recruitment, reduction in operating costs, and less-stringent regulatory frameworks than the US and Western Europe. Besides reducing costs, sponsors attribute improved quality and reduction in the time to market as major drivers for outsourcing their business functions to CROs, CDMOs, and CMOs. Hence, many pharmaceutical and biotechnology companies and academic institutes opt to outsource functions like manufacturing, clinical trial management, R&D, and drug discovery to CROs.

Challenges: High degree of consolidation acts as an entry barrier for new entrants

The top players in this market are large and well-established and enjoy a high degree of brand loyalty. New entrants in this market compete with existing players and set themselves apart by developing innovative product offerings. The high degree of consolidation acts as a major entry barrier for new entrants, which in turn, is expected to restrict investments and thus slow down the growth potential of this market.

“Assays, Kits, & Reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service, in 2019”

The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service. In 2019, the assays, kits, & reagents segment accounted for this market's largest share. The frequent purchase of these consumables as compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the important factors driving the growth of this market segment.

“Cell line testing segment accounted for the largest share in the market, by application, in 2019”

Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segment's growth.

“North America is the largest regional market for mycoplasma testing market”

The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global mycoplasma testing market. The large share of this regional segment can primarily be attributed to the growth in biotechnology and pharmaceutical industries, the high adoption rate of novel technologies, and the large number of life science research studies conducted in this region.

Mycoplasma Testing Market  by Region

Some key players in the mycoplasma testing market (2020- 2025)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD Million)

Segments covered

Product, technique, application, end user, and region

Geographies covered

North America, Europe, Asia Pacific, and Rest of the Wo

Companies covered

Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International, Inc. (US), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (US), Bionique Testing Laboratories, Inc. (US), InvivoGen (US), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd. (Israel), Creative Bioarray (US), Mycoplasma Experience (UK), Norgen Biotek Corp. (Canada), Agilent Technologies (US), Biotools B & M Labs, S.A. (Spain), Eurofins Scientific (Luxembourg), GeneCopoeia, Inc. (US), GenBio (Canada), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (US), Sartorius AG (Germany), Savyon Diagnostics (Israel), Nelson Laboratories Fairfield, Inc. (US), Clongen Laboratories, Inc. (US), and ScienCell Research Laboratories, Inc. (Canada).

This report categorizes the mycoplasma testing market into the following segments and subsegments:

By Product & Service

  • Assays, Kits, & Reagents
    • NAT assays, kits, & reagents
    • ELISA assays, kits, & reagents
    • Elimination Kits
    • Stains
    • Other assays, kits, & reagents
  • Instruments
  • Services

By Technique

  • NAT
  • ELISA
  • Staining
  • Other technique

By Application

  • Cell line testing
  • Virus Testing
  • End- of- Production cell testing

By End User

  • Pharmaceutical & Biotechnology Companies
  • Cell Banks & Laboratories
  • Contract Research Organizations
  • Academic Research Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments

  • In July 2020, Roche Diagnostics launched Cobas 6800, a fully automated system in India.
  • In July 2020, Creative Bioarray launched a full range of cell-based services
  • In January 2020, Charles River Laboratories (US) acquired HemaCare Corporation (US)

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 24)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           FIGURE 1 INCLUSIONS & EXCLUSIONS
           1.2.1 MARKETS COVERED
                    FIGURE 2 MYCOPLASMA TESTING MARKET SEGMENTATION
           1.2.2 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH DATA
           FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 5 MYCOPLASMA TESTING MARKET: BOTTOM-UP APPROACH
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 6 MYCOPLASMA TESTING MARKET: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 36)
    FIGURE 8 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2020 VS. 2025 (USD MILLION)
    FIGURE 9 MYCOPLASMA TESTING MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
    FIGURE 10 MYCOPLASMA TESTING MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
    FIGURE 11 MYCOPLASMA TESTING MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 39)
    4.1 MYCOPLASMA TESTING MARKET OVERVIEW
           FIGURE 12 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
    4.2 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
           FIGURE 13 NAT ASSAYS, KITS, & REAGENTS SEGMENT TO COMMAND THE LARGEST MARKET SHARE IN 2019
    4.3 MYCOPLASMA TESTING MARKET, BY TECHNIQUE, 2020 VS. 2025
           FIGURE 14 GROWING ADOPTION OF NAT IN EMERGING ECONOMIES TO DRIVE MARKET GROWTH
    4.4 MYCOPLASMA TESTING MARKET, BY REGION, 2020 VS. 2025
           FIGURE 15 ASIA PACIFIC MARKET TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 42)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 16 MYCOPLASMA TESTING MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing concerns over cell culture contamination
                    5.2.1.2 Growth in pharmaceutical and biotechnology industries
                               TABLE 1 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2019–2020
                    5.2.1.3 Rising pharmaceutical R&D activities and investments
                               FIGURE 17 INCIDENCE OF THE TOP 10 FATAL CONDITIONS GLOBALLY, 2019 (%)
                               TABLE 2 RISING CANCER INCIDENCE, BY COUNTRY/REGION, 2018 VS. 2025
                               FIGURE 18 R&D SPENDING BY PHRMA MEMBER-COMPANIES, 2001–2019 (USD BILLION)
                               TABLE 3 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2018
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Globalization of clinical trials and R&D and harmonization of regulations resulting in increased outsourcing
                    5.2.2.2 Emerging economies
           5.2.3 CHALLENGES
                    5.2.3.1 High degree of consolidation acts as an entry barrier for new entrants
    5.3 IMPACT OF COVID-19 ON THE MYCOPLASMA TESTING MARKET
    5.4 VALUE CHAIN ANALYSIS
           FIGURE 19 VALUE CHAIN ANALYSIS OF THE MYCOPLASMA TESTING MARKET
           FIGURE 20 RESTRAINTS IN THE VALUE CHAIN, BY STAGE
    5.5 SUPPLY CHAIN ANALYSIS
           FIGURE 21 SUPPLY CHAIN ANALYSIS OF THE MYCOPLASMA TESTING MARKET
    5.6 ECOSYSTEM ANALYSIS
           FIGURE 22 ECOSYSTEM ANALYSIS OF THE MYCOPLASMA TESTING MARKET

6 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE (Page No. - 51)
    6.1 INTRODUCTION
           TABLE 4 AVERAGE SELLING PRICE
           TABLE 5 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
    6.2 ASSAYS, KITS, & REAGENTS
           6.2.1 INCREASING ADOPTION OF NAT TO DRIVE MARKET GROWTH
                    TABLE 6 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                    TABLE 7 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.2.2 NAT ASSAYS, KITS, & REAGENTS
                    TABLE 8 NAT ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.2.3 ENZYME-LINKED IMMUNOSORBENT ASSAYS, KITS, & REAGENTS
                    TABLE 9 ENZYME-LINKED IMMUNOSORBENT ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.2.4 ELIMINATION KITS
                    TABLE 10 ELIMINATION KITS MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.2.5 STAINS
                    TABLE 11 MYCOPLASMA TESTING STAINS MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.2.6 OTHER ASSAYS, KITS, & REAGENTS
                    TABLE 12 OTHER ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
    6.3 INSTRUMENTS
           6.3.1 DEMAND FOR FULLY AUTOMATED INSTRUMENTS IS INCREASING IN RESEARCH APPLICATIONS
                    TABLE 13 MYCOPLASMA TESTING INSTRUMENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
    6.4 SERVICES
           6.4.1 LACK OF INFRASTRUCTURE AND EXPERTISE HAVE DRIVEN RELIANCE ON SERVICE PROVIDERS
                    TABLE 14 MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2018–2025 (USD MILLION)

7 MYCOPLASMA TESTING MARKET, BY TECHNIQUE (Page No. - 59)
    7.1 INTRODUCTION
           TABLE 15 MYCOPLASMA TESTING MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
    7.2 NUCLEIC ACID TESTING
           7.2.1 NAT SEGMENT DOMINATED THE MARKET IN 2019
           TABLE 16 NAT-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)
    7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
           7.3.1 ELISA IS WIDELY USED FOR MYCOPLASMA DETECTION IN RESEARCH APPLICATIONS
                    TABLE 17 ELISA-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)
    7.4 STAINING
           7.4.1 STAINING OF CULTURES CAN PROVIDE RAPID RESULTS
                    TABLE 18 STAINING-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)
    7.5 OTHER TECHNIQUES
           TABLE 19 OTHER TECHNIQUES-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)

8 MYCOPLASMA TESTING MARKET, BY APPLICATION (Page No. - 64)
    8.1 INTRODUCTION
           TABLE 20 MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
    8.2 CELL LINE TESTING
           8.2.1 RAPID GROWTH IN THE BIOPHARMACEUTICAL INDUSTRY TO DRIVE THE DEMAND FOR CELL LINE TESTING
                    TABLE 21 MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY REGION, 2018–2025 (USD MILLION)
                    TABLE 22 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY, 2018–2025 (USD MILLION)
                    TABLE 23 EUROPE: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY, 2018–2025 (USD MILLION)
                    TABLE 24 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY, 2018–2025 (USD MILLION)
    8.3 VIRUS TESTING
           8.3.1 RISING DEMAND FOR VACCINES TO DRIVE MARKET GROWTH
                    TABLE 25 KEY VIRUS TESTING PRODUCTS/SERVICES OFFERED BY MARKET PLAYERS
                    TABLE 26 MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY REGION, 2018–2025 (USD MILLION)
                    TABLE 27 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY, 2018–2025 (USD MILLION)
                    TABLE 28 EUROPE: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY, 2018–2025 (USD MILLION)
                    TABLE 29 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY, 2018–2025 (USD MILLION)
    8.4 END-OF-PRODUCTION CELL TESTING
           8.4.1 GROWING DEMAND FOR BIOLOGICS TO DRIVE MARKET GROWTH
                    TABLE 30 MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY REGION, 2018–2025 (USD MILLION)
                    TABLE 31 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018–2025 (USD MILLION)
                    TABLE 32 EUROPE: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018–2025 (USD MILLION)
                    TABLE 33 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018–2025 (USD MILLION)

9 MYCOPLASMA TESTING MARKET, BY END USER (Page No. - 72)
    9.1 INTRODUCTION
           TABLE 34 MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES FORM THE LARGEST END-USER SEGMENT IN THE MYCOPLASMA TESTING MARKET
                    FIGURE 23 R&D INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY, 2012–2026 (USD BILLION)
                    TABLE 35 PHARMACEUTICAL PATENT GRANTS, 2017 VS. 2019, BY COUNTRY
                    TABLE 36 MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018–2025 (USD MILLION)
    9.3 CONTRACT RESEARCH ORGANIZATIONS
           9.3.1 GROWTH IN OUTSOURCING TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
                    TABLE 37 MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION)
    9.4 ACADEMIC & RESEARCH INSTITUTES
           9.4.1 ACADEMIC AND RESEARCH INSTITUTES PROVIDE VARIOUS MICROBIOLOGY TESTING SERVICES
                    TABLE 38 MYCOPLASMA TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION)
    9.5 CELL BANKS & LABORATORIES
           9.5.1 IT IS ESTIMATED THAT ABOUT 5–30% OF THE WORLD'S CELL LINES ARE CONTAMINATED WITH MYCOPLASMAS
                    TABLE 39 MYCOPLASMA TESTING MARKET FOR CELL BANKS & LABORATORIES, BY REGION, 2018–2025 (USD MILLION)

10 MYCOPLASMA TESTING MARKET, BY REGION (Page No. - 79)
     10.1 INTRODUCTION
               TABLE 40 MYCOPLASMA TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)
     10.2 NORTH AMERICA
               FIGURE 24 NORTH AMERICA: MYCOPLASMA TESTING MARKET SNAPSHOT
               TABLE 41 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
               TABLE 42 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
               TABLE 43 NORTH AMERICA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 44 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
               TABLE 45 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.2.1 US
                       10.2.1.1 US is the largest market for mycoplasma testing products and services in North America
                                   TABLE 46 US: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 47 US: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 48 US: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 49 US: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.2.2 CANADA
                       10.2.2.1 Increasing pharma and biotech R&D investments to drive market growth
                                   TABLE 50 CANADA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 51 CANADA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 52 CANADA: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 53 CANADA: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.3 EUROPE
               TABLE 54 EUROPE: MYCOPLASMA TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
               TABLE 55 EUROPE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
               TABLE 56 EUROPE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 57 EUROPE: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
               TABLE 58 EUROPE: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.1 GERMANY
                       10.3.1.1 Germany accounted for the largest share of the European market in 2019
                                   TABLE 59 GERMANY: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 60 GERMANY: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 61 GERMANY: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 62 GERMANY: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.2 UK
                       10.3.2.1 Growth in the life science industry to support market growth in the UK
                                   TABLE 63 UK: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 64 UK: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 65 UK: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 66 UK: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.3 FRANCE
                       10.3.3.1 Increasing investments in life science R&D to support market growth in France
                                   TABLE 67 FRANCE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 68 FRANCE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 69 FRANCE: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 70 FRANCE: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.4 ITALY
                       10.3.4.1 Italy is one of the leaders in life science research in Europe
                                   TABLE 71 ITALY: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 72 ITALY: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 73 ITALY: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 74 ITALY: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.5 SPAIN
                       10.3.5.1 Increasing opportunities for generics and biosimilars manufacturers to support market growth in Spain
                                   TABLE 75 SPAIN: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 76 SPAIN: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 77 SPAIN: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 78 SPAIN: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.3.6 REST OF EUROPE
                                   TABLE 79 ROE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 80 ROE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 81 ROE: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 82 ROE: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.4 ASIA PACIFIC
               FIGURE 25 APAC: MYCOPLASMA TESTING MARKET SNAPSHOT
               TABLE 83 APAC: MYCOPLASMA TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
               TABLE 84 APAC: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
               TABLE 85 APAC: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 86 APAC: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
               TABLE 87 APAC: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.1 CHINA
                       10.4.1.1 China accounted for the largest share of the APAC market in 2019
                                   TABLE 88 CHINA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 89 CHINA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 90 CHINA: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 91 CHINA: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.2 JAPAN
                       10.4.2.1 Increasing demand for technologically advanced research products to drive market growth in Japan
                                   TABLE 92 JAPAN: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 93 JAPAN: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 94 JAPAN: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 95 JAPAN: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.3 INDIA
                       10.4.3.1 Growing CRO base in India to support market growth
                                   TABLE 96 INDIA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                                   TABLE 97 INDIA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                                   TABLE 98 INDIA: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                                   TABLE 99 INDIA: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                       TABLE 100 ROAPAC: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
                       TABLE 101 ROAPAC: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                       TABLE 102 ROAPAC: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                       TABLE 103 ROAPAC: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.5 REST OF THE WORLD
               TABLE 104 ROW: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
               TABLE 105 ROW: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
               TABLE 106 ROW: MYCOPLASMA TESTING MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
               TABLE 107 ROW: MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 114)
     11.1 OVERVIEW
               FIGURE 26 KEY DEVELOPMENTS IN THE MYCOPLASMA TESTING MARKET (JANUARY 2017–SEPTEMBER 2020)
     11.2 MYCOPLASMA TESTING MARKET SHARE ANALYSIS
               FIGURE 27 MYCOPLASMA TESTING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
     11.3 COMPANY EVALUATION QUADRANT
             11.3.1 DEFINITION AND METHODOLOGY
             11.3.2 VENDOR DIVE OVERVIEW
                       11.3.2.1 Stars
                       11.3.2.2 Emerging leaders
                       11.3.2.3 Pervasive
                       11.3.2.4 Participants
                                   FIGURE 28 MYCOPLASMA TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
     11.4 COMPETITIVE SCENARIO
             11.4.1 PRODUCT/SERVICE LAUNCHES
                       TABLE 108 PRODUCT/SERVICE LAUNCHES & REGULATORY APPROVALS (JANUARY 2017–SEPTEMBER 2020)
             11.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
                       TABLE 109 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (JANUARY 2017–SEPTEMBER 2020)
             11.4.3 ACQUISITIONS
                       TABLE 110 ACQUISITIONS (JANUARY 2017–SEPTEMBER 2020)
             11.4.4 EXPANSIONS
                       TABLE 111 EXPANSIONS (JANUARY 2017–SEPTEMBER 2020)

12 COMPANY PROFILES (Page No. - 119)
     12.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MNM view)*
             12.1.1 MERCK KGAA
                       FIGURE 29 MERCK KGAA: COMPANY SNAPSHOT (2019)
             12.1.2 ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMAN-LA ROCHE LTD.)
                       FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
             12.1.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                       FIGURE 31 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2019)
             12.1.4 LONZA GROUP LTD.
                       FIGURE 32 LONZA GROUP LTD.: COMPANY SNAPSHOT (2019)
             12.1.5 THERMO FISHER SCIENTIFIC, INC.
                       FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
             12.1.6 EUROFINS SCIENTIFIC GROUP
                       FIGURE 34 EUROFINS SCIENTIFIC GROUP: COMPANY SNAPSHOT (2019)
             12.1.7 SARTORIUS STEDIM BIOTECH S.A.
                       FIGURE 35 SARTORIUS STEDIM BIOTECH S.A.: COMPANY SNAPSHOT (2019)
             12.1.8 AGILENT TECHNOLOGIES, INC.
                       FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019)
             12.1.9 MERIDIAN BIOSCIENCE, INC.
                       FIGURE 37 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2019)
             12.1.10 AMERICAN TYPE CULTURE COLLECTION
     12.2 OTHER PLAYERS
             12.2.1 BIONIQUE TESTING LABORATORIES, INC.
             12.2.2 INVIVOGEN
             12.2.3 PROMOCELL GMBH
             12.2.4 BIOLOGICAL INDUSTRIES ISRAEL BEIT HAEMEK LTD.
             12.2.5 CLONGEN LABORATORIES, LLC.
             12.2.6 CREATIVE BIOARRAY
             12.2.7 NELSON LABORATORIES FAIRFIELD, INC. (A PART OF SOTERA HEALTH)
             12.2.8 NORGEN BIOTEK CORPORATION
             12.2.9 BIOTOOLS B & M LABS, S.A.
             12.2.10 GENBIO (A PART OF EXONHIT THERAPEUTICS SA)
             12.2.11 GENECOPOEIA, INC.
             12.2.12 MINERVA BIOLABS GMBH
             12.2.13 MYCOPLASMA EXPERIENCE
             12.2.14 SAVYON DIAGNOSTICS
             12.2.15 SCIENCELL RESEARCH LABORATORIES

*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 148)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the mycoplasma testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to i identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information and assess future prospects.

The following is a breakdown of the primary respondents:

Mycoplasma Testing Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the mycoplasma testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the mycoplasma testing market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Global Mycoplasma testing market Size: Top Down Approach

    Mycoplasma Testing Market  Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Data Triangulation

    After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Report Objectives

    • To define, describe, and forecast the global mycoplasma testing market based on product & service, technique, application, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders
    • To forecast the size of the global mycoplasma testing market with respect to four main regions (along with countries), namely, North America, Europe, the Asia Pacific, and the Rest of the World
    • To profile the key players in the global mycoplasma testing market and comprehensively analyze their core competencies and market shares
    • To track and analyze competitive developments such as agreements, partnerships, acquisitions, product launches, and expansions in the global mycoplasma testing market

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

    Country Information

    • Mycoplasma testing market size and growth rate estimates for counties in Rest of Europe, the Rest of Asia Pacific and Rest of the World

    Company profiles

    • Additional five company profiles of players operating in the mycoplasma testing market
COVID-19

Get in-depth analysis of the COVID-19 impact on the Mycoplasma Testing Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Mycoplasma Testing Market

Request For Special Pricing
Report Code
BT 3371
Published ON
Nov, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Mycoplasma Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved